Researchers from Sungkyunkwan University and the Ulsan National Institute of Science and Technology (UNIST) have patented compounds reported to be useful for the treatment of Staphylococcus aureus infections.
Chong Kun Dang Pharmaceutical Corp. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of fibrosis, neurodegeneration, nutrition, endocrine, immunological, inflammatory, psychiatric and renal disorders, among others.
Aligos Therapeutics Inc. has patented programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.
Researchers from Cyclone Therapeutics Inc. and the Scripps Research Institute have disclosed tetracycline derivatives reported to be useful for the treatment of fragile X syndrome, rheumatoid arthritis and Alzheimer’s disease.
Shanghai Institute of Organic Chemistry and the University of Michigan have prepared and tested new cyclin-dependent kinase 12 (CDK12) and 13 (CDK13) inhibitors reported to be useful for the treatment of cancer.
Work at Blacksmith Medicines Inc. has led to the identification of new bacterial UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors reported to be useful for the treatment of Pseudomonas aeruginosa infection, lung diseases and infectious pneumonia.
A Chong Kun Dang Pharmaceutical Corp. patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, ulcerative colitis, graft-vs.-host disease, systemic lupus erythematosus and osteoarthritis, among others.
RSS